Clearside Biomedical, Inc. (CLSD)
NASDAQ: CLSD · IEX Real-Time Price · USD
1.230
-0.010 (-0.81%)
At close: Jul 2, 2024, 4:00 PM
1.305
+0.075 (6.10%)
After-hours: Jul 2, 2024, 7:57 PM EDT
Company Description
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space.
It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema.
It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.
The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences.
Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Clearside Biomedical, Inc.
| Country | United States |
| Founded | 2011 |
| IPO Date | Jun 2, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 30 |
| CEO | Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D. |
Contact Details
Address: 900 North Point Parkway, Suite 200 Alpharetta, Georgia 30005 United States | |
| Phone | 678-270-3631 |
| Website | clearsidebio.com |
Stock Details
| Ticker Symbol | CLSD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001539029 |
| CUSIP Number | 185063104 |
| ISIN Number | US1850631045 |
| Employer ID | 45-2437375 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D. | President, Chief Executive Officer and Director |
| Charles A. Deignan | Chief Financial Officer |
| Dr. Thomas A. Ciulla M.B.A., M.D. | Chairman of Scientific Advisory Board |
| Jenny R. Kobin | Head of Investor Relations |
| Rick McElheny | Vice President of Corporate Development |
| Rafael V. Andino | Senior Vice President of Engineering and Manufacturing |
| Susan L. Coultas Ph.D. | Chief Clinical Officer |
| Dr. Ngai Hang Chong M.B.A., M.D. | Chief Medical Officer |
| Leslie B. Zacks | Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 20, 2024 | 8-K | Current Report |
| May 10, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 10, 2024 | 10-Q | Quarterly Report |
| May 9, 2024 | 8-K | Current Report |
| Apr 26, 2024 | ARS | Filing |
| Apr 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 26, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 16, 2024 | 8-K | Current Report |
| Mar 12, 2024 | 10-K | Annual Report |
| Mar 12, 2024 | 8-K | Current Report |